ID   166-32
AC   CVCL_B0NC
DR   ATCC; HB-12476
DR   Wikidata; Q108819399
RX   Patent=US6956107;
RX   PubMed=10456004;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12476.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized Fab antigen binding domain of the therapeutic antibody lampalizumab (FCFD4514S; RG7417) which was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P00746; Human CFD.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
CA   Hybridoma
DT   Created: 23-09-21; Last updated: 21-03-23; Version: 4
//
RX   Patent=US6956107;
RA   Fung M.S.C., Sun W.N.C., Sun C.R.-Y.;
RT   "Inhibitors of complement activation.";
RL   Patent number US6956107, 18-Oct-2005.
//
RX   PubMed=10456004; DOI=10.1016/S0041-1345(99)00297-3;
RA   Tanhehco E.J., Kilgore K.S., Liff D.A., Murphy K.L., Fung M.S.C.,
RA   Sun W.N.C., Sun C.R.-Y., Lucchesi B.R.;
RT   "The anti-factor D antibody, MAb 166-32, inhibits the alternative
RT   pathway of the human complement system.";
RL   Transplant. Proc. 31:2168-2171(1999).
//